logo

For the Inventor, By the Inventor

Cheshire, United Kingdom

John Fritiof Pontén

This inventor holds 15 USPTO granted patents and 3 published patent applications. Top assignee: Astrazeneca Ab. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Fritiof Pontén. Retrieved from https://idiyas.com/inventor/john-fritiof-pontén

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 5

Forward Citations = 118(Granted Patents)


Company Filing History:

goldMedal15 out of 1,534 
 
Astrazeneca Ab
 patents

Years Active: 2016-2024

Loading Chart...
15 patents (USPTO):Explore Patents
1. 12054465 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2024-08-06),
2. 11814359 - Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-11-14),
3. 11773069 - Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-10-03),
4. 11680049 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-20),
5. 11673872 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-13),
6. 11673871 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-13),
7. 11667615 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-06),
8. 11655224 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),
9. 11655223 - Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),
10. 11655222 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),
11. 11655221 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),
12. 11117874 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2021-09-14),
13. 10669245 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors (2020-06-02),
14. 10287258 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2019-05-14),
15. 9522894 - [object Object] (2016-12-20),

Title: John Fritiof Pontén: Innovator in Pharmaceutical Chemistry

Introduction

John Fritiof Pontén is a notable inventor based in Cheshire, GB, recognized for his significant contributions to pharmaceutical chemistry. With a total of 15 patents to his name, he has made strides in developing innovative compounds that address critical health issues.

Latest Patents

Pontén's latest patents include compounds such as certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides, which serve as dipeptidyl peptidase 1 inhibitors. These compounds are particularly relevant in treating and preventing respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). The patents detail their utility in therapy, the pharmaceutical compositions containing them, and the processes for preparing such compounds.

Career Highlights

Pontén has established a successful career at AstraZeneca AB, where he has been instrumental in advancing research and development in the pharmaceutical sector. His work has not only contributed to the company's portfolio but has also had a broader impact on public health.

Collaborations

Throughout his career, Pontén has collaborated with esteemed colleagues such as Stephen Connolly and Steven Swallow. These partnerships have fostered innovation and have been crucial in the development of his patented compounds.

Conclusion

John Fritiof Pontén's work exemplifies the importance of innovation in the pharmaceutical industry. His contributions continue to pave the way for advancements in treatments for respiratory diseases, showcasing the vital role of inventors in improving health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…